Literature DB >> 12566307

Frequent display of human papillomavirus type 16 E6-specific memory t-Helper cells in the healthy population as witness of previous viral encounter.

Marij J P Welters1, Annemieke de Jong, Susan J F van den Eeden, Jeanette M van der Hulst, Kitty M C Kwappenberg, Sabrin Hassane, Kees L M C Franken, Jan Wouter Drijfhout, Gert Jan Fleuren, Gemma Kenter, Cornelis J M Melief, Rienk Offringa, Sjoerd H van der Burg.   

Abstract

Genital human papillomavirus (HPV) infection is common and the majority of infected individuals successfully deal with this virus. Clearance of HPV is presumably mediated by T cells but HPV-16-specific T-cell memory was usually detected in patients with progressive disease and not in healthy subjects, suggesting that HPV-immunity comes too late. We now show the presence of HPV-16 E6-specific memory T-helper (Th) responses in a major fraction (12 of 20) of healthy individuals by application of the IFN-gamma-ELISPOT assay. Although nearly all E6-peptides were recognized, the majority of the responders targeted peptide sequences of the COOH-terminal half (E6(81-158)) of HPV-16 E6. In a direct comparison, the presence of HPV-16 E6-specific T cells coincided with HPV-16 E2-specific T-cell reactivity in healthy individuals, whereas hardly any HPV-16 E7-specific Th immunity was found. This indicates that the induction of T-cell reactivity against HPV-16 E7 is suboptimal during infection when compared with that against HPV-16 E2 and HPV-16 E6. In conclusion, the presence of HPV-16 E6-specific Th memory in the healthy population demonstrates that HPV infection leads to T-cell immunity against immediate early proteins expressed during infection. Because this HPV-16 E6-specific T-cell immunity was frequently detected in healthy subjects, our data suggest that the observed IFN-gamma-producing proliferating T cells circulating in the peripheral blood play a role in protection against persistent HPV infection and associated development of malignancies.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12566307

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  58 in total

1.  Human papillomavirus 16-associated cervical intraepithelial neoplasia in humans excludes CD8 T cells from dysplastic epithelium.

Authors:  Cornelia L Trimble; Rachael A Clark; Christopher Thoburn; Nicole C Hanson; Jodie Tassello; Denise Frosina; Ferdynand Kos; Jessica Teague; Ying Jiang; Nicole C Barat; Achim A Jungbluth
Journal:  J Immunol       Date:  2010-10-29       Impact factor: 5.422

Review 2.  [Prophylactic and therapeutic vaccines against human papilloma virus].

Authors:  A E Albers; T K Hoffmann; J P Klussmann; A M Kaufmann
Journal:  HNO       Date:  2010-08       Impact factor: 1.284

3.  CD4+ T cells against human papillomavirus-18 E7 in patients with high-grade cervical lesions associate with the absence of the virus in the cervix.

Authors:  Samantha Seresini; Massimo Origoni; Luigi Caputo; Flavia Lillo; Renato Longhi; Simone Vantini; Anna Maria Paganoni; Maria Pia Protti
Journal:  Immunology       Date:  2010-06-02       Impact factor: 7.397

Review 4.  Warts and all: human papillomavirus in primary immunodeficiencies.

Authors:  Jennifer W Leiding; Steven M Holland
Journal:  J Allergy Clin Immunol       Date:  2012-10-01       Impact factor: 10.793

Review 5.  Immune therapy for human papillomaviruses-related cancers.

Authors:  Ricardo Rosales; Carlos Rosales
Journal:  World J Clin Oncol       Date:  2014-12-10

Review 6.  Human Immunodeficiency Virus and Human Papilloma Virus - why HPV-induced lesions do not spontaneously resolve and why therapeutic vaccination can be successful.

Authors:  Sjoerd H van der Burg; Joel M Palefsky
Journal:  J Transl Med       Date:  2009-12-18       Impact factor: 5.531

Review 7.  [Humoral and cellular immune response in HPV vaccination].

Authors:  E Glastetter; A M Kaufmann
Journal:  Hautarzt       Date:  2007-06       Impact factor: 0.751

8.  Reversal of papilloma growth in rabbits therapeutically vaccinated against E6 with naked DNA and/or vesicular stomatitis virus vectors.

Authors:  Janet L Brandsma; Mark Shlyankevich; Yuhua Su; Daniel Zelterman; John K Rose; Linda Buonocore
Journal:  Vaccine       Date:  2009-07-15       Impact factor: 3.641

9.  Failure of gamma interferon but not interleukin-10 expression in response to human papillomavirus type 11 E6 protein in respiratory papillomatosis.

Authors:  James A DeVoti; Bettie M Steinberg; David W Rosenthal; Lynda Hatam; Andrea Vambutas; Allan L Abramson; Mark J Shikowitz; Vincent R Bonagura
Journal:  Clin Diagn Lab Immunol       Date:  2004-05

Review 10.  Recent advances in strategies for immunotherapy of human papillomavirus-induced lesions.

Authors:  Shreya Kanodia; Diane M Da Silva; W Martin Kast
Journal:  Int J Cancer       Date:  2008-01-15       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.